Updated on 27 September 2026
Drug Repurposing & Epigenetic Screening Platform for Age-Related Degenerative Diseases
Managing director and CFO at Oliba Healthcare and Pharma
Roma, Italy
About
ADAPTherapeutics is a University of Padova spin-off developing disease-modifying therapies for age-related degenerative diseases, including neurodegenerative, cardiovascular and metabolic conditions. We act upstream of the disease. Instead of treating cellular damage, we identify drugs able to correct the pathological genomic remodeling that drives it.
Our proprietary platform defines disease-specific molecular signatures from human patient samples. It then screens already-commercialized compounds through Drug-seq transcriptomic profiling and computational analysis. Because we start from drugs with established safety profiles, we shorten timelines, reduce risk and accelerate regulatory pathways. Our pipeline includes vorinostat (SAHA), decitabine and JQ1, now in pre-clinical validation.
We offer pharma and biotech partners phenotypic and transcriptomic screening, indication expansion and repurposing studies, and co-development of new therapeutic assets. Our team combines expertise in epigenetics with international experience in regulatory affairs and market access. Contact us to explore a collaboration.
Type
- Research & Development
- Testing & Analysis
Attached files
Organisation
Similar opportunities
Partnership
Partnering Opportunity: Repurposed Epigenetic Drugs for Age-Related Degenerative Diseases
Alessandro Monaco
Managing director and CFO at Oliba Healthcare and Pharma
Roma, Italy
Service
Network-Based Drug Repurposing and Indication Expansion
Federico Reali
Group Leader at Fondazione The Microsoft Research -University of Trento Centre for Computational and Systems Biology
Rovereto, Italy
Product
Elisa Stellaria Grassi
Associate Researcher at Istituto Auxologico Italiano
Milan, Italy